Can-Fite BioPharma (NYSE:CANF) Now Covered by assumed coverage on shares of Can-Fite BioPharma (NYSE:CANFGet Rating) in a report released on Sunday. The brokerage set a “sell” rating on the stock.

Shares of CANF opened at $0.90 on Friday. The firm has a market cap of $24.46 million, a price-to-earnings ratio of -1.30 and a beta of 1.86. The company has a fifty day moving average of $1.00. Can-Fite BioPharma has a fifty-two week low of $0.78 and a fifty-two week high of $2.62.

Can-Fite BioPharma Company Profile (Get Rating)

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.

Recommended Stories

Receive News & Ratings for Can-Fite BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can-Fite BioPharma and related companies with's FREE daily email newsletter.